



17373-Review

Quotes Excluded
Bibliography Excluded10%
SIMILAR

Match Overview

1	CrossCheck 171 words Michiels, J.J., "Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction..."	3%
2	CrossCheck 50 words Jan Michiels, "Clinical and Laboratory Features, Pathobiology of Platelet-Mediated Thrombosis and Bleeding Complications"	1%
3	CrossCheck 42 words Jan Jacques Michiels, "Review", Platelets, 3/1/2004	1%
4	Internet 23 words crawled on 06-Aug-2010 www.haematologica.org	<1%
5	CrossCheck 22 words Jan Jacques Michiels, "Platelet-mediated erythromelalgia, cerebral, ocular and coronary microvascular ischemic and thrombotic complications"	<1%
6	Internet 19 words crawled on 16-May-2013 jco.ascopubs.org	<1%

Name of journal: World Journal of Critical Care Medicine

ESPS Manuscript NO: 17373

Columns: Minireviews

Clinical manifestations and treatment recommendations in thrombocythemia of various myeloproliferative neoplasms

Jan Jacques Michiels

Abstract

Prospective studies indicate that the risk of microvascular and major thrombosis in untreated thrombocythemia in various myeloproliferative neoplasms (MPN-T) is not age dependent and causally related to platelet-mediated thrombosis in early, intermediate and advanced stages of thrombocythemia in myeloproliferative neoplasms (MPN-T). If left untreated both microvascular and major thrombosis frequently do occur in MPN-T but can easily be cured and prevented by low dose



The spectrum of clinical manifestations and laboratory features in the pre



网页

新闻

图片

视频

更多

搜索工具

获得 9 条结果 (用时 0.56 秒)

[PDF] The 2006 → 2008 European Clinical, Molecular and ...
[esciencecentral.org/.../the--european-clinical-molecular-and-pat...](#) 翻译此页

2015年2月20日 - whereas **Essential Thrombocythemia** (ET), **Polycythemia Vera** (PV) ...
PV stages that have important prognostic and **therapeutic implications**. trilinear
myeloproliferative disorder (MPD) [15] due to one hypothetical cause Anno 2014 ...
related **clinical presentation** or **laboratory findings** and are to be.

Publications - University of Antwerp

<https://www.uantwerpen.be/en/rg/vaxinfectio/research...and.../publications/>
Expert review of anti-infective **therapy**-issn 1744-8336-13(2015),p. 279- ... Essential
Differences in **Clinical** and Bone Marrow **Features** in BCR/ABL-Positive ... Changing
concepts of diagnostic criteria of **myeloproliferative disorders** and the molecular etiology
and ... -positive **essential thrombocythemia** and **polycythemia vera**

Changing Concepts of Diagnostic Criteria of ... - Karger

www.karger.com/Article/Pdf/358580 - 翻译此页
2014年8月7日 - **Essential thrombocythemia** · JAK2 V617F mutation · JAK2 ...
Myeloproliferative neoplasms · **Polycythemia vera** · ... 66.249.78.46 - 2/18/2015 4:24:58
AM ... to diagnose, classify and stage the broad **spectrum** of MPN **Therapeutic**
implications anno **clinical**, **laboratory** and bone marrow **features** of pro-

Changing concepts of diagnostic criteria of ... - PubFacts

www.pubfacts.com/.../Changing-Concepts-of-Diagnostic-Criteri... 翻译此页
The **Polycythemia Vera** Study Group (PVSG) and WHO classifications distinguished ...
myeloproliferative neoplasms (MPN) **essential thrombocythemia** (ET), ... ET phenotypes
at **clinical** and bone marrow level when the integrated WHO and ... are recommended to
diagnose, classify and stage the broad **spectrum** of MPN of ...

Essential thrombocythemia Publications and Abstracts

www.pubfacts.com/search/Essential+thrombocythemia 翻译此页
Therapy for myeloproliferative neoplasms: when, which agent, and how? Hematology Am
... **Myeloproliferative neoplasms**, including **polycythemia vera** (PV), **essential** ...
Zhongguo Shi Yan Xue Ye Xue Za Zhi 2015 Jan;23(1):278-84 **Clinical manifestations**

[网页](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多 ▾](#)[搜索工具](#)

找到约 1,740,000 条结果 (用时 0.87 秒)

Chronic Myeloproliferative Neoplasms Treatment - National ...

www.cancer.gov/.../myeloproliferative/hp/chronic-treatment-pd... ▾ [翻译此页](#)

2015年4月2日 - Chronic Myeloproliferative Neoplasms Treatment-for health professionals (PDQ®) ... [1] Patients with p. vera and essential thrombocythemia have marked increases of ... Patients have an increased risk of cardiovascular and thrombotic events ... Postsurgery outcomes in patients with polycythemia vera and ...

Thrombotic disease in the myeloproliferative neoplasms

asheducationbook.hematologylibrary.org/content/.../571.full.p... ▾ [翻译此页](#)

作者: A Falanga - 2012 - 被引用次数: 48 - 相关文章

Thrombosis is a leading cause of morbidity and mortality in patients with Philadelphia chromosome-negative ... due to an acquired activated protein C resistance result in a highly prothrombotic scenario in patients with polycythemia vera and essential thrombocythemia. ... burden, has begun to be under active investigation.

Management of Essential Thrombocythemia

asheducationbook.hematologylibrary.org/content/.../1/215.full ▾ [翻译此页](#)

作者: F Cervantes - 2011 - 被引用次数: 25 - 相关文章

2011年12月10日 - Patients are considered at high risk of thrombosis if they are older than 60 ... The role in ET therapy of new drugs such as pegylated IFN or the JAK2 ... the term "hemorrhagic thrombocythemia," is a myeloproliferative neoplasm ... the mutated

[网页](#)[新闻](#)[图片](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 109,000 条结果 (用时 0.49 秒)

Google 学术: Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia patients

... thrombocythemia and a high risk of thrombosis - Cortelazzo - 被引用次数: 697

... risk factor for thrombosis in essential thrombocythemia: ... - Carobbio - 被引用次数: 257

... thrombosis in patients with polycythemia vera and ... - De Stefano - 被引用次数: 151

Management of Essential Thrombocythemia

asheducationbook.hematologylibrary.org/content/.../1/215.full ▾ 翻译此页

作者: F Cervantes - 2011 - 被引用次数: 25 - 相关文章

2011年12月10日 - Patients are considered at high risk of thrombosis if they are older than 60 ... The role in ET therapy of new drugs such as pegylated IFN or the JAK2 ... the term "hemorrhagic thrombocythemia," is a myeloproliferative neoplasm ... the mutated allele burden is the more important contributor to MPN phenotype.

The Myeloproliferative Neoplasms

www.clevelandclinicmeded.com/.../chronic-myeloproliferative-... ▾ 翻译此页

作者: A Advani - 相关文章

JAK2 allele burden might be important in identifying high-risk patients with PV or ET (i.e., those at risk for requiring treatment with ... The hemocrit is directly proportional to the